{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T08:27:58Z","timestamp":1782289678901,"version":"3.54.5"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.017","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:04:58Z","timestamp":1254218698000},"page":"S231-S238","source":"Crossref","is-referenced-by-count":18,"special_numbering":"S3","title":["Burkitt Lymphoma\/Leukemia: Improving Prognosis"],"prefix":"10.3816","volume":"9","author":[{"given":"Vaishalee P.","family":"Kenkre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.017_bib1","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/ajcp\/101.2.130","article-title":"L3 acute lymphoblastic leukemia. Comparison with small noncleaved cell lymphoma involving the bone marrow","volume":"101","author":"Dayton","year":"1994","journal-title":"Am J Clin Pathol"},{"key":"10.3816\/CLM.2009.s.017_bib2","series-title":"I. Pathology and Genetics of Tumors of Hematopoietic and Lymphoid Tissues","first-page":"181","article-title":"Burkitt Lymphoma","author":"Diebold","year":"2001"},{"key":"10.3816\/CLM.2009.s.017_bib3","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/1097-0142(19830515)51:10<1777::AID-CNCR2820511003>3.0.CO;2-E","article-title":"The discovery of Burkitt's lymphoma","volume":"51","author":"Burkitt","year":"1983","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.017_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1146\/annurev.pathol.1.110304.100209","article-title":"Spectrum of Epstein-Barr virus-associated diseases","volume":"1","author":"Kutok","year":"2006","journal-title":"Annu Rev Pathol"},{"key":"10.3816\/CLM.2009.s.017_bib5","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2004-02-0405","article-title":"Adult Burkitt leukemia and lymphoma","volume":"104","author":"Blum","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib6","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/blood-2008-03-145128","article-title":"A prospective clinicopathologic study of dose-modified CODOX-M\/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC\/NCRI LY10 trial)","volume":"112","author":"Mead","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib7","doi-asserted-by":"crossref","first-page":"5595","DOI":"10.1038\/sj.onc.1204595","article-title":"Translocations involving c-myc and c-myc function","volume":"20","author":"Boxer","year":"2001","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2009.s.017_bib8","doi-asserted-by":"crossref","first-page":"d250","DOI":"10.2741\/A239","article-title":"Myc and the cell cycle","volume":"3","author":"Amati","year":"1998","journal-title":"Front Biosci"},{"key":"10.3816\/CLM.2009.s.017_bib9","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1038\/sj.onc.1202393","article-title":"The opposing roles of the Akt and c-Myc signalling pathways in survival from CD95-mediated apoptosis","volume":"17","author":"Rohn","year":"1998","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2009.s.017_bib10","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1200\/JCO.2000.18.21.3707","article-title":"Molecular biology of Burkitt's lymphoma","volume":"18","author":"Hecht","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib11","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1073\/pnas.85.8.2748","article-title":"Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma","volume":"85","author":"Neri","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.3816\/CLM.2009.s.017_bib12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1038\/sj.onc.1202468","article-title":"Deregulation of the proto-oncogene c-myc through t(8;22) translocation in Burkitt's lymphoma","volume":"18","author":"Gerbitz","year":"1999","journal-title":"Oncogene"},{"key":"10.3816\/CLM.2009.s.017_bib13","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1056\/NEJMoa055759","article-title":"Molecular diagnosis of Burkitt's lymphoma","volume":"354","author":"Dave","year":"2006","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.017_bib14","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1182\/blood-2008-01-136465","article-title":"Molecular profiling of pediatric mature B-cell lymphoma treated in population-based prospective clinical trials","volume":"112","author":"Klapper","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib15","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1200\/JCO.1986.4.12.1732","article-title":"Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine","volume":"4","author":"Murphy","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib16","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib17","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2009.s.017_bib18","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1182\/blood-2006-07-036673","article-title":"Results of the randomized international FAB\/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients","volume":"109","author":"Patte","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib19","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1200\/JCO.1986.4.6.847","article-title":"Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types)","volume":"4","author":"Bernstein","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib20","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V85.3.664.bloodjournal853664","article-title":"Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols","volume":"85","author":"Soussain","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib21","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1182\/blood.V87.2.495.bloodjournal872495","article-title":"Improved outcome in adult B-cell acute lymphoblastic leukemia","volume":"87","author":"Hoelzer","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib22","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib23","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1200\/JCO.2001.19.20.4014","article-title":"Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251","volume":"19","author":"Lee","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib24","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1002\/cncr.20143","article-title":"Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251","volume":"100","author":"Rizzieri","year":"2004","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.017_bib25","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.017_bib26","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1182\/blood.V110.11.2825.2825","article-title":"Long-term outcome after hyper-CVAD and rituximab chemoimmunotherapy for Burkitt (BL) or Burkitt-like (BLL) leukemia\/lymphoma and mature B-cell acute lymphocytic leukemia (BALL)","volume":"110","author":"Thomas","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib27","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood.V110.11.518.518","article-title":"High survival rate in adult Burkitt's lymphoma\/leukemia and diffuse large B-cell lymphoma with mediastinal involvement","volume":"110","author":"Hoelzer","year":"2007","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.017_bib28","first-page":"449s","article-title":"Efficacy and toxicity of dose-adjusted EPOCH-rituximab in adults with newly diagnosed Burkitt Lymphoma","volume":"25","author":"Dunleavy","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib29","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1182\/blood.V80.5.1130.1130","article-title":"High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study","volume":"80","author":"Nademanee","year":"1992","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1200\/JCO.1993.11.5.931","article-title":"Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study","volume":"11","author":"Freedman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib31","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/sj.leu.2403733","article-title":"Short intensive sequential therapy followed by autologous stem cell transplantation in adult Burkitt, Burkittlike and lymphoblastic lymphoma","volume":"19","author":"van Imhoff","year":"2005","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.017_bib32","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bmt.1703891","article-title":"An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation","volume":"31","author":"Peniket","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLM.2009.s.017_bib33","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia","volume":"94","author":"Cortes","year":"2002","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.017_bib34","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/339215","article-title":"2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer","volume":"34","author":"Hughes","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.3816\/CLM.2009.s.017_bib35","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1001\/jama.285.13.1736","article-title":"Association of cancer with AIDSrelated immunosuppression in adults","volume":"285","author":"Frisch","year":"2001","journal-title":"JAMA"},{"key":"10.3816\/CLM.2009.s.017_bib36","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib37","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/apc.2007.0124","article-title":"Improving outcomes for patients with Burkitt lymphoma and HIV","volume":"22","author":"Blinder","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.3816\/CLM.2009.s.017_bib38","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cncr.23522","article-title":"High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients","volume":"113","author":"Oriol","year":"2008","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.017_bib39","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/cncr.11628","article-title":"Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma","volume":"98","author":"Wang","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLM.2009.s.017_bib40","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.molimm.2006.05.007","article-title":"Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab","volume":"44","author":"Carnahan","year":"2007","journal-title":"Mol Immunol"},{"key":"10.3816\/CLM.2009.s.017_bib41","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1200\/JCO.2007.15.3528","article-title":"Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study","volume":"26","author":"Raetz","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.017_bib42","doi-asserted-by":"crossref","first-page":"4347","DOI":"10.1182\/blood.V93.12.4347","article-title":"Hypermethylation of the DAPkinase CpG island is a common alteration in B-cell malignancies","volume":"93","author":"Katzenellenbogen","year":"1999","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib43","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1182\/blood.V91.5.1680","article-title":"p16\/INK4a and p15\/INK4b gene methylation and absence of p16\/INK4a mRNA and protein expression in Burkitt's lymphoma","volume":"91","author":"Klangby","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib44","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10637-006-9000-0","article-title":"Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia\/lymphoma agents against human leukemia\/lymphoma cell lines","volume":"25","author":"Kano","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.3816\/CLM.2009.s.017_bib45","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1093\/jnci\/90.15.1146","article-title":"Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model","volume":"90","author":"Smith","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2009.s.017_bib46","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1182\/blood-2002-07-2044","article-title":"Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells","volume":"101","author":"Serafeim","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.017_bib47","first-page":"4342","article-title":"Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor","volume":"58","author":"Orlowski","year":"1998","journal-title":"Cancer Res"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T15:47:05Z","timestamp":1590162425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":47,"alternative-id":["S1557919011703456"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.017","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}